Hoe verhoudt CLVS.Q's PS Ratio zich tot zijn concurrenten?

CLVS.Q is een goede waarde op basis van zijn Price-To-Sales Ratio (0x) vergeleken met het gemiddelde van gelijken (0.6x).

Hoe verhoudt CLVS.Q's PS Ratio zich tot andere bedrijven in de US Biotechs industrie?

CLVS.Q is een goede waarde op basis van de Price-To-Sales -ratio ( 0 x) vergeleken met het US Biotechs -industriegemiddelde ( 10.3 x).

Wat is CLVS.Q's PS Ratio vergeleken met zijn Fair PS Ratio? Dit is de verwachte PS Ratio, rekening houdend met de verwachte winstgroei van het bedrijf, winstmarges en andere risicofactoren.

Onvoldoende gegevens om de Price-To-Sales Fair Ratio van { CLVS.Q te berekenen voor waarderinganalyse.

Wat is de reële prijs van CLVS.Q als we kijken naar de toekomstige kasstromen? Voor deze schatting gebruiken we een Discounted Cash Flow-model.

Onvoldoende gegevens om de reële waarde van CLVS.Q te berekenen voor waarderingsanalyse.

Wat is de 12-maandsprognose van de analisten en hebben we enig statistisch vertrouwen in het consensuskoersdoel?

Er zijn onvoldoende gegevens om een prijsvoorspelling te tonen.

Clovis Oncology (OTCPK:CLVS.Q) - Aandelenkoers, Nieuws & Analyse

CLVS.Q Overzicht aandelen

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Meer informatie

CLVS.Q fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	0/6
Dividenden	0/6

Beloningen

De winst is de afgelopen 5 jaar met 5.6% per jaar gegroeid

Risicoanalyse

Negatief eigen vermogen

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

Heeft geen betekenisvolle marktkapitalisatie ( $2M )

De laatste financiële rapporten zijn ouder dan 6 maanden

Clovis Oncology, Inc. Concurrenten

Biocept

NasdaqCM:BIOC

US$2.7m

Ensysce Biosciences

NasdaqCM:ENSC

US$9.7m

Biodexa Pharmaceuticals

NasdaqCM:BDRX

US$3.3m

Peak Bio

OTCPK:PKBO

US$1.6m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Clovis Oncology
Historische aandelenkoersen
Huidige aandelenkoers	US$0.015
52 Week Hoogtepunt	US$2.87
52 Week Laag	US$0.01
Bèta	0.66
11 maand verandering	-40.00%
3 maanden verandering	-28.57%
1 Jaar Verandering	-99.39%
33 jaar verandering	-99.77%
5 jaar verandering	-99.97%
Verandering sinds IPO	-99.88%

Recent nieuws en updates

Recent updates

Clovis Oncology rises on clinical supply agreement with Isotopia

Sep 21

Clovis stock rises 15% as Rubraca shows survival benefit as maintenance therapy for ovarian cancer in trial

Sep 12

Clovis Oncology: Needs Some Encouraging Data Quickly

Aug 11

These Analysts Think Clovis Oncology, Inc.'s (NASDAQ:CLVS) Sales Are Under Threat

Aug 10

News Flash: 4 Analysts Think Clovis Oncology, Inc. (NASDAQ:CLVS) Earnings Are Under Threat

Feb 24

Buying Beaten Down Clovis Oncology Stock Ahead Of 2022 Catalysts

Jan 11

Clovis Oncology Is Now Discounted And Offers A Great Risk-Reward

Dec 30

Clovis Oncology Stock: Only Glimmers Of Hope

Oct 07

Clovis: Compelling With Upcoming Catalysts

Jul 30

Here's Why Shareholders May Want To Be Cautious With Increasing Clovis Oncology, Inc.'s (NASDAQ:CLVS) CEO Pay Packet

Jun 17

Clovis Oncology and Inovio gain amid Reddit chatter

Jun 09

Clovis Oncology: Another Upcycle Coming

May 08

Clovis Oncology drops 7% as Rubraca sales missed estimates amid continued COVID-19 headwinds

May 05

Don't Ignore The Fact That This Insider Just Sold Some Shares In Clovis Oncology, Inc. (NASDAQ:CLVS)

Mar 17

How Much Did Clovis Oncology's(NASDAQ:CLVS) Shareholders Earn From Share Price Movements Over The Last Three Years?

Feb 22

Clovis Oncology: Recent Rally Already Has Me Changing My Game Plan

Jan 31

Clovis Oncology: Finally Green Shoots May Be On The Horizon

Jan 29

Clovis Oncology reports preliminary Q4 Rubraca revenue between $43.0M to $43.5M

Jan 11

What Kind Of Investors Own Most Of Clovis Oncology, Inc. (NASDAQ:CLVS)?

Dec 31

Clovis Oncology submits FAP-2286 applications for therapeutic and imaging clinical trial

Dec 29

Clovis stock rises as rubraca shows survival benefit in late-stage ovarian cancer study

Dec 21

Clovis Oncology existing holder purchases additional $7.5M convertible senior notes

Nov 25

Clovis Oncology: Cash Position Is Tight, We Question Management's Guidance

Nov 09

Clovis Oncology: Reloading Before And After Q3 Earnings For The Long Term

Nov 06

Clovis Oncology EPS beats by $0.11, misses on revenue

Nov 05

Rendement voor aandeelhouders

	CLVS.Q	US Biotechs	US Markt
7D	18.1%	2.5%	1.0%
1Y	-99.4%	15.6%	31.4%

Rendement versus industrie: CLVS.Q presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 15.6 % opleverde.

Rendement versus markt: CLVS.Q presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 31.4 % opleverde.

Prijsvolatiliteit

Is CLVS.Q's price volatile compared to industry and market?
CLVS.Q volatility
CLVS.Q Average Weekly Movement	61.3%
Biotechs Industry Average Movement	9.9%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.3%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van CLVS.Q is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van CLVS.Q is het afgelopen jaar gestegen van 39% naar 61%.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2009	413	Patrick Mahaffy	www.clovisoncology.com

Clovis Oncology, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Clovis Oncology zich tot de beurswaarde?
CLVS.Q fundamentele statistieken
Marktkapitalisatie	US$2.18m
Inkomsten(TTM)	-US$251.91m
Inkomsten(TTM)	US$133.02m

0.0x

P/S-verhouding

0.0x

Koers/Winstverhouding

Is CLVS.Q overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
CLVS.Q resultatenrekening (TTM)
Inkomsten	US$133.02m
Kosten van inkomsten	US$31.59m
Brutowinst	US$101.43m
Overige uitgaven	US$353.33m
Inkomsten	-US$251.91m

Laatst gerapporteerde inkomsten

Sep 30, 2022

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-1.73
Brutomarge	76.25%
Nettowinstmarge	-189.37%
Schuld/Eigen Vermogen Verhouding	-158.0%

Hoe presteerde CLVS.Q op de lange termijn?

Bekijk historische prestaties en vergelijking

CLVS.Q Overzicht aandelen

Beloningen

Risicoanalyse

Clovis Oncology, Inc. Concurrenten

NasdaqCM:BIOC

US$2.7m

NasdaqCM:ENSC

US$9.7m

NasdaqCM:BDRX

US$3.3m

OTCPK:PKBO

US$1.6m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Clovis Oncology, Inc.(OTCPK:CLVS.Q) dropped from NASDAQ Composite Index

Clovis Oncology, Inc.(NasdaqGS:CLVS) dropped from S&P TMI Index

Nasdaq to Delist Common Stock of Clovis Oncology from Exchange

Clovis Oncology, Inc. Filed for Bankruptcy

Clovis Oncology, Inc. Filed for Bankruptcy

Clovis Oncology, Inc. Discusses the Overall Survival (Os) Data from the ARIEL3 Clinical Trial with FDA t

Recent updates

Clovis Oncology, Inc.(OTCPK:CLVS.Q) dropped from NASDAQ Composite Index

Clovis Oncology, Inc.(NasdaqGS:CLVS) dropped from S&P TMI Index

Nasdaq to Delist Common Stock of Clovis Oncology from Exchange

Clovis Oncology, Inc. Filed for Bankruptcy

Clovis Oncology, Inc. Filed for Bankruptcy

Clovis Oncology, Inc. Discusses the Overall Survival (Os) Data from the ARIEL3 Clinical Trial with FDA t

Insufficient new directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Clovis Oncology, Inc Announces Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM Congress

Cvis Oncncology, Inc. Announces Positive Top-Line Data from the Phase 3, Open-Label, Multicenter, Randomized Triton3 Trial

Clovis Oncology rises on clinical supply agreement with Isotopia

Clovis Oncology, Inc. Submits Applications for Rubraca® Label Expansion in the US and European Union as First-Line Maintenance Treatment in Women with Advanced Ovarian Cancer

Clovis Oncology’s Rubraca (Rucaparib) as First-Line Maintenance Treatment Improves Progression-Free Survival in Women with Advanced Ovarian Cancer Across Disease Risk Subgroups

Clovis stock rises 15% as Rubraca shows survival benefit as maintenance therapy for ovarian cancer in trial

Consensus revenue estimates fall by 13%

Clovis Oncology: Needs Some Encouraging Data Quickly

These Analysts Think Clovis Oncology, Inc.'s (NASDAQ:CLVS) Sales Are Under Threat

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Clovis Oncology Q2 2022 Earnings Preview

EMA recommends restricted use of Clovis cancer drug

Clovis Oncology, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Clovis Oncology climbs 34% as shareholders reject reverse stock split

Clovis Oncology Highlights Phase 1 Data from Ongoing Clinical Studies of Targeted Radiotherapy Candidate FAP-2286 At SNMMI Annual Meeting

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Clovis: Shifting Toward Nuclear Medicine

Clovis Oncology, Inc. to Report Q1, 2022 Results on May 04, 2022

Clovis Oncology Highlights Presentations on FAP-2286 and Rubraca® (Rucaparib) at the AACR Annual Meeting 2022

Clovis Oncology: Forging A Fresh Perspective

Clovis Oncology, Inc. Announces A Trial-In-Progress Poster Detailing the Phase 1 Portion of the LuMIERE Clinical Study for Its Targeted Radiotherapy Candidate FAP-2286

Full year 2021 earnings: EPS exceeds analyst expectations

Consensus revenue estimates fall by 18%

News Flash: 4 Analysts Think Clovis Oncology, Inc. (NASDAQ:CLVS) Earnings Are Under Threat

Price target increased to US$6.33

Clovis Oncology, Inc. Provides Preliminary Unaudited Earnings Guidance for the Quarter and Year Ended December 31, 2021

Buying Beaten Down Clovis Oncology Stock Ahead Of 2022 Catalysts

Clovis Oncology Is Now Discounted And Offers A Great Risk-Reward

Price target increased to US$6.33

Insufficient new directors

Third quarter 2021 earnings released: US$0.56 loss per share (vs US$0.89 loss in 3Q 2020)

Price target increased to US$6.38

Clovis Oncology Stock: Only Glimmers Of Hope

Clovis Oncology, Inc. Announces Availability of and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Switzerland

Clovis Oncology, Inc. Provides an Update on the Clinical Development Programs

Price target decreased to US$5.90

Second quarter 2021 earnings released: US$0.61 loss per share (vs US$1.15 loss in 2Q 2020)

Clovis: Compelling With Upcoming Catalysts

Clovis Oncology Announces LuMIERE Clinical Trial Evaluating Novel Peptide-Targeted Radionuclide Therapy FAP-2286 Now Open for Enrollment

Here's Why Shareholders May Want To Be Cautious With Increasing Clovis Oncology, Inc.'s (NASDAQ:CLVS) CEO Pay Packet

Clovis Oncology and Inovio gain amid Reddit chatter

Clovis Oncology, Inc. Highlights Rubraca® (rucaparib) and Lucitanib Data at 2021 ASCO Annual Meeting

Clovis Oncology: Another Upcycle Coming

Consensus forecasts updated

First quarter 2021 earnings released: US$0.64 loss per share (vs US$1.39 loss in 1Q 2020)

Price target decreased to US$6.35

Clovis Oncology drops 7% as Rubraca sales missed estimates amid continued COVID-19 headwinds

Clovis Oncology, Inc. Announces First Presentation of Data from the Phase 3 ARIEL4 Study of Rubraca® (rucaparib) at the Society of Gynecologic Oncology Virtual Annual Meeting on Women’s Cancer

Don't Ignore The Fact That This Insider Just Sold Some Shares In Clovis Oncology, Inc. (NASDAQ:CLVS)

Insider recently sold US$56k worth of stock